Barry D. Quart
2022
In 2022, Barry D. Quart earned a total compensation of $1.1M as Former Chief Executive Officer at Heron Therapeutics, a 79% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $386,400 |
|---|---|
| Salary | $736,000 |
| Other | $23,304 |
| Total | $1,145,704 |
Quart received $736K in salary, accounting for 64% of the total pay in 2022.
Quart also received $386.4K in non-equity incentive plan and $23.3K in other compensation.
Rankings
In 2022, Barry D. Quart's compensation ranked 2,769th out of 5,736 executives tracked by ExecPay. In other words, Quart earned more than 51.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,769 out of 5,736 | 52nd |
Division Manufacturing | 1,543 out of 3,125 | 51st |
Major group Chemicals And Allied Products | 716 out of 1,416 | 49th |
Industry group Drugs | 668 out of 1,317 | 49th |
Industry Pharmaceutical Preparations | 482 out of 963 | 50th |
Source: SEC filing on May 1, 2023.
Quart's colleagues
We found two more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2022.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020